Robert P. DeCresce, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. A prospective evaluation of the effect of sample collection site on intraoperative parathormone monitoring during parathyroidectomy.
   Beyer TD, Chen E, Ata A, DeCresce R, Prinz RA, Solorzano CC.
   Surgery.
   2008 Oct
   144(4):504-9; discussion 509-10
   
2. Induction of transplantation tolerance by allogeneic donor-derived CD4(+)CD25(+)Foxp3(+) regulatory T cells
   Velásquez-Lopera MM, Eaton VL, Lerret NM, Correa LA, Decresce RP, García LF, Jaramillo A
   Transpl Immunol
   2008 May
   19(2):127-35
   
3. Enhanced allograft survival and modulation of T-cell alloreactivity induced by inhibition of MMP/ADAM enzymatic activity
   Eaton VL, Lerret NM, Velásquez-Lopera MM, John R, Caicedo M, DeCresce RP, Jaramillo A
   Am J Transplant
   2008 Mar
   8(3):507-16
   

• To watch a brief video of Robert P. DeCresce, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• When your doctor orders a laboratory test or does a biopsy, we interpret the tests and also provide feedback to physicians when they have questions about tests. We also help pick the tests that are going to be used at the medical center and evaluate them to make sure that they work appropriately and help physicians make the diagnoses.

  What we do now that’s very different than in the past — before we would make diagnoses that were pretty broad and general, and now we’re asked to make diagnoses that are quite specific because many of the drugs that are used are actually aimed and targeted at a specific kind of cancer, a specific subtype of a disease. And so now it’s really, really important that we tell the clinician exactly what type or subtype, which might make them eligible for a therapy or might not make them respond to a very expensive therapy. So we can really help direct the clinician to pick the right therapy for a patient.